ArticlePloS one2011
Economic returns to investment in AIDS treatment in low and middle income countries.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Estimated economic burden of genital herpes and HIV attributable to herpes simplex virus type 2 infections in 90 low- and middle-income countries: A modeling study.PLoS medicine · 2022Pooled it
- Innovative financing for HIV response in sub-Saharan Africa.Journal of global health · 2016Pooled it
- Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens.Medicine · 2015Pooled it
- Interventions for improving employment outcomes for workers with HIV.The Cochrane database of systematic reviews · 2015Pooled it
- A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts.Therapeutic advances in drug safety · 2025Article
- Perception and experience of HIV-induced stigma among people with HIV seeking healthcare in Ghana.BMC health services research · 2024Article
- Intergenerational spillover effects of antiretroviral therapy in sub-Saharan Africa: a scoping review and future directions for research.BMJ global health · 2023Article
- Article
- Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Assessing the costs and efficiency of HIV testing and treatment services in rural Malawi: implications for future "test and start" strategies.BMC health services research · 2020Article
- Work and home productivity of people living with HIV in Zambia and South Africa.AIDS (London, England) · 2019Article
- Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal.BMJ global health · 2019Article
- Frontloading HIV financing maximizes the achievable impact of HIV prevention.Journal of the International AIDS Society · 2018Article
- Understanding the dynamic interactions driving the sustainability of ART scale-up implementation in Uganda.Global health research and policy · 2018Article
- Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study.PLoS medicine · 2017Article
- Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach.BMC health services research · 2017Article
- Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa: investment needs, population health gains, and cost-effectiveness.AIDS (London, England) · 2016Article
- Article
- Long-term financing needs for HIV control in sub-Saharan Africa in 2015-2050: a modelling study.BMJ open · 2016Article
- Survival benefits of antiretroviral therapy in Brazil: a model-based analysis.Journal of the International AIDS Society · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the early 2000s, aid organizations and developing country governments have invested heavily in AIDS treatment. By 2010, more than five million people began receiving antiretroviral therapy (ART)--yet each year, 2.7 million people are becoming newly infected and another two million are dying without ever having received treatment. As the need for treatment grows without commensurate increase in the amount of available resources, it is critical to assess the health and economic gains being realized from increasingly large investments in ART. This study estimates total program costs and compares them with selected economic benefits of ART, for the current cohort of patients whose treatment is cofinanced by the Global Fund to Fight AIDS, Tuberculosis and Malaria. At end 2011, 3.5 million patients in low and middle income countries will be receiving ART through treatment programs cofinanced by the Global Fund. Using 2009 ART prices and program costs, we estimate that the discounted resource needs required for maintaining this cohort are $14.2 billion for the period 2011-2020. This investment is expected to save 18.5 million life-years and return $12 to $34 billion through increased labor productivity, averted orphan care, and deferred medical treatment for opportunistic infections and end-of-life care. Under alternative assumptions regarding the labor productivity effects of HIV infection, AIDS disease, and ART, the monetary benefits range from 81 percent to 287 percent of program costs over the same period. These results suggest that, in addition to the large health gains generated, the economic benefits of treatment will substantially offset, and likely exceed, program costs within 10 years of investment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.